Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- MTPC Appoints Development Division Manager as New Representative Director
February 7, 2014
- Takeda CFO Says Midterm Strategy Not Affected by Halt of TAK-875 Trials
February 7, 2014
- Astellas to Bring Global Development, Regulatory Affairs Functions Under Control of Chief Medical Officer
February 7, 2014
- JCR, GSK Ink Research Support Agreement to Establish New Technology
February 6, 2014
- Kyorin Pushes Easy to Use Inhaler Flutiform, Aims for Higher Market Penetration
February 6, 2014
- Fujifilm Pharma Gets Japan Distribution Rights for Sosei’s Oropharyngeal Candidiasis Drug
February 6, 2014
- Kyowa Kirin Begins Japan PIII Trial of ARQ 197 for Hepatocellular Cancer
February 6, 2014
- Eisai to File Lenvatinib for Approval in Japan, US, Europe as Early as June
February 6, 2014
- NDA for Lorcaserin Expected to Be Filed in Japan in FY2016 or Later: Eisai
February 5, 2014
- 396 Eisai Workers Take Voluntary Retirement, FY2013 Net Profit Forecast Revised Downward
February 5, 2014
- DSP Expands Collaboration with Edison for Development of Mitochondrial Disease Treatment
February 5, 2014
- Kyowa Kirin to Integrate Research and Development Divisions
February 4, 2014
- Drug Wholesalers Laud Medical Fee Cuts to Fix Lengthy Haggling, Pharmacy Chains Vexed by Rule
February 4, 2014
- Kyowa Kirin Drug Prices Expected to Slip by 7% Due to NHI Price Revision
February 4, 2014
- Asahi Kasei Pharma to Discontinue Development of Teribone Transdermal Patch Formulation in Japan
February 4, 2014
- Impact of FDA’s Ranbaxy Ban on Daiichi Sankyo Earnings “Unavoidable”: Mr Sakai
February 3, 2014
- Daiichi Sankyo to Shift to IFRS Starting from FY2013
February 3, 2014
- CSL Behring Launches Hizentra, 1st SC Immunoglobulin Therapy in Japan
February 3, 2014
- Teijin Picks Another Pharma Maven for President
February 3, 2014
- Chugai President Mum on Kadcyla Launch Timing, Price Talks with Regulators Still Ongoing
February 3, 2014
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…